mRNA and Delivery / Lipids and LNP Excipients
ALC-0315
Quick view. ALC-0315 (CAS 2036272-55-4) is listed for identity-scoped inquiry through OROGO. Current availability, exact chemical form, specification and packaging are confirmed for each request; this listing makes no stock or suitability claim. Catalog target purity: Specification by inquiry. Availability: Inquiry only — contact OROGO to confirm current availability.
Request a quote Review request checklist
Catalog status
Scope. "Available for inquiry" is not a stock claim. Operating tier is a catalog-merchandising priority. Development phase and program context are shown only where the reviewed catalog source provides a mapping; they describe the chemistry platform and do not claim that OROGO supplies the named program.
| Supply status | Available for inquiry |
|---|---|
| Operating tier | Core |
| Reviewed supporting program count | 1 |
| Representative chemistry-platform program | tozinameran (Comirnaty) |
| Highest development phase | Marketed |
| CAS status | Published registry number |
Product profile
ALC-0315 is classified as mrna and delivery / lipids and lnp excipients (Formula C48H95NO5; molecular weight 766.30).
ALC-0315 is supplied for research use within the Specialty Amphiphilic Compounds product family.
For ALC-0315, confirm the current specification, storage conditions and downstream-method compatibility before routine use.
Names and search terms
Useful catalog search terms
- 2036272-55-4
Physicochemical data
| Reviewed identity | ALC-0315 |
|---|---|
| PubChem CID | 122666778 |
| InChI | InChI=1S/C48H95NO5/c1-5-9-13-17-19-27-37-45(35-25-15-11-7-3)47(51)53-43-33-23-21-29-39-49(41-31-32-42-50)40-30-22-24-34-44-54-48(52)46(36-26-16-12-8-4)38-28-20-18-14-10-6-2/h45-46,50H,5-44H2,1-4H3 |
| InChIKey | QGWBEETXHOVFQS-UHFFFAOYSA-N |
| SMILES | CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.